Last reviewed · How we verify
AND017 capsules QW
AND017 capsules QW is a SGLT2 inhibitor Small molecule drug developed by Kind Pharmaceuticals LLC. It is currently in Phase 2 development for Type 2 diabetes, Atrial fibrillation for stroke prevention.
AND017 capsules QW is a small molecule that targets the SGLT2 receptor.
AND017 capsules are a small molecule treatment for Renal Anemia in patients with chronic kidney disease on dialysis. They are administered once a week (QW) as part of a clinical study comparing their efficacy and safety to other treatments, including epoetin alfa, darbepoetin alfa, and Mircera.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | AND017 capsules QW |
|---|---|
| Sponsor | Kind Pharmaceuticals LLC |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
It works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is particularly effective in patients with type 2 diabetes. By reducing glucose reabsorption, AND017 capsules QW also has a mild diuretic effect, which can help reduce blood pressure.
Approved indications
- Type 2 diabetes
- Atrial fibrillation for stroke prevention
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Hypotension
- Increased urination
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AND017 capsules QW CI brief — competitive landscape report
- AND017 capsules QW updates RSS · CI watch RSS
- Kind Pharmaceuticals LLC portfolio CI
Frequently asked questions about AND017 capsules QW
What is AND017 capsules QW?
How does AND017 capsules QW work?
What is AND017 capsules QW used for?
Who makes AND017 capsules QW?
What drug class is AND017 capsules QW in?
What development phase is AND017 capsules QW in?
What are the side effects of AND017 capsules QW?
What does AND017 capsules QW target?
Related
- Drug class: All SGLT2 inhibitor drugs
- Target: All drugs targeting SGLT2
- Manufacturer: Kind Pharmaceuticals LLC — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes
- Indication: Drugs for Atrial fibrillation for stroke prevention
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing